Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cancer Research

• Publication date

  2003-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12839954
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Negative feedback regulation of wild-type p53 biosynthesis

  2007cited by this paper
• Establishment and characterization of a new mammary adenocarcinoma cell line derived from MMTV neu transgenic mice

  2004cited by this paper
• Real time in vivo quantitation of tumor angiogenesis.

  2003cited by this paper
• p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products

  2002cited by this paper
• Expression of p14ARF overcomes tumor resistance to p53.

  2002cited by this paper
• CARF Is a Novel Protein That Cooperates with Mouse p19 ARF (Human p14 ARF ) in Activating p53*

  2002cited by this paper
• p53-independent apoptosis is induced by the p19ARF tumor suppressor.

  2002cited by this paper
• Growth suppression by a p14ARF exon 1β adenovirus in human tumor cell lines of varying p53 and Rb status

  2002cited by this paper
• Adenovirus-Mediated p14 ARF Gene Transfer Cooperates with Ad5CMV-p53 to Induce Apoptosis in Human Cancer Cells

  2002cited by this paper
• Function and dysfunction of the human oncoprotein MDM2.

  2002cited by this paper
• Regulation and function of the p53 tumor suppressor protein.

  2001cited by this paper
• The p14ARF Tumor Suppressor Protein Facilitates Nucleolar Sequestration of Hypoxia-inducible Factor-1α (HIF-1α) and Inhibits HIF-1-mediated Transcription*

  2001cited by this paper
• Human ARF protein interacts with Topoisomerase I and stimulates its activity

  2001cited by this paper
• Defining the molecular basis of Arf and Hdm2 interactions.

  2001cited by this paper
• Human ARF binds E2F1 and inhibits its transcriptional activity

  2001cited by this paper
• Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.

  2001cited by this paper
• MdmX Binding to ARF Affects Mdm2 Protein Stability and p53 Transactivation*

  2001cited by this paper
• The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha ) and inhibits HIF-1-mediated transcription.

  2001cited by this paper
• The p16INK4alpha/p19ARF gene mutations are infrequent and are mutually exclusive to p53 mutations in Indian oral squamous cell carcinomas.

  2000cited by this paper
• INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene.

  2000cited by this paper
• Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

  2000cited by this paper
• p53-independent functions of the p19(ARF) tumor suppressor.

  2000cited by this paper
• Sensitization of tumors to chemotherapy through gene therapy.

  2000cited by this paper
• Cooperative Signals Governing ARF-Mdm2 Interaction and Nucleolar Localization of the Complex

  2000cited by this paper
• A translation repressor element resides in the 3′ untranslated region of human p53 mRNA

  1999cited by this paper
• Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification.

  1999cited by this paper
• Sensitization of rat glioblastoma multiforme to cisplatin in vivo following restoration of wild-type p53 function.

  1998cited by this paper
• ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.

  1998cited by this paper
• Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

  1998cited by this paper
• The Human ARF Cell Cycle Regulatory Gene Promoter Is a CpG Island Which Can Be Silenced by DNA Methylation and Down-Regulated by Wild-Type p53

  1998cited by this paper
• DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2.

  1997cited by this paper
• Participation of the human p53 3′UTR in translational repression and activation following γ‐irradiation

  1997cited by this paper
• Mdm2 promotes the rapid degradation of p53

  1997cited by this paper
• Translational regulation of human p53 gene expression.

  1996cited by this paper
• Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

  1996cited by this paper
• Use of wild‐type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53

  1995cited by this paper
• The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes

  1994cited by this paper
• Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

  1994cited by this paper
• Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

  1994cited by this paper
• Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.

  1994cited by this paper
• Dorsal skinfold chamber technique for intravital microscopy in nude mice.

  1993cited by this paper
• p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.

  1993cited by this paper
• The p53-mdm-2 autoregulatory feedback loop.

  1993cited by this paper
• Association of induction of a fully tumorigenic phenotype in murine radiation‐induced T‐lymphoma cells with loss of differentiation antigens, gain of CD44, and alterations in p53 protein levels

  1992cited by this paper
• p53 mutations in human cancers.

  1991cited by this paper

• Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer

  2020cites this paper
• Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer

  2019cites this paper
• Inhibition of MDM 2 via Nutlin-3 A : A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM 2-Induced Inactivation of Wild-Type P 53

  2018cites this paper
• Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53

  2018cites this paper
• The Roles of p53 in Mitochondrial Dynamics and Cancer Metabolism: The Pendulum between Survival and Death in Breast Cancer?

  2018cites this paper
• What's new in mesothelioma.

  2018cites this paper
• IRES-Mediated Protein Translation Overcomes Suppression by the p14ARF Tumor Suppressor Protein

  2017cites this paper
• miRNA regulation is important for DNA damage repair and recognition in malignant pleural mesothelioma

  2017cites this paper
• Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy

  2016influential citation
• Intratumoral Immunization by p19Arf and Interferon-β Gene Transfer in a Heterotopic Mouse Model of Lung Carcinoma

  2016cites this paper
• microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma

  2016cites this paper
• MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53

  2015cites this paper
• Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression

  2015cites this paper
• Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer.

  2013cites this paper
• Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development

  2012cites this paper
• Intravital microscopy in the mouse dorsal chamber model for the study of solid tumors.

  2011cites this paper
• The Cyclin-Dependent Kinase Inhibitor and Tumor Suppressor Locus p16/INK4Ap14ARF and Regulation of the Transition Into and Out of the Cell Cycle

  2011cites this paper
• Functional Analysis of the p53 Pathway in Neuroblastoma Cells Using the Small-Molecule MDM2 Antagonist Nutlin-3

  2011cites this paper
• Activation of endogenous p53 by combined p19Arf gene transfer and nutlin-3 drug treatment modalities in the murine cell lines B16 and C6

  2010cites this paper
• Role of the tumor suppressor ARF and the p 53-pathway in retinoblastoma development

  2009cites this paper
• Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.

  2007cites this paper
• Macrophage-mediated bystander effect triggered by tumor cell apoptosis.

  2007cites this paper
• Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas

  2007cites this paper
• INGN 201 (Advexin®): adenoviral p53 gene therapy for cancer

  2006cites this paper
• DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer

  2006cites this paper
• Regulation of p14ARF Through Subnuclear Compartmentalization

  2006cites this paper
• Changes in endosome-lysosome pH accompanying pre-malignant transformation.

  2005cites this paper
• Doxycycline potentiates antitumor effect of cyclophosphamide in mice.

  2005cites this paper
• DNA damage disrupts the p14ARF-B23(nucleophosmin) interaction and triggers a transient subnuclear redistribution of p14ARF.

  2005cites this paper
• A novel gene transfer strategy that combines promoter and transgene activities for improved tumor cell inhibition

  2005cites this paper